CA2455753A1 - Nouveaux derives de la 2,4-diaminothiazole - Google Patents

Nouveaux derives de la 2,4-diaminothiazole Download PDF

Info

Publication number
CA2455753A1
CA2455753A1 CA002455753A CA2455753A CA2455753A1 CA 2455753 A1 CA2455753 A1 CA 2455753A1 CA 002455753 A CA002455753 A CA 002455753A CA 2455753 A CA2455753 A CA 2455753A CA 2455753 A1 CA2455753 A1 CA 2455753A1
Authority
CA
Canada
Prior art keywords
alkyl
alkoxy
aryl
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002455753A
Other languages
English (en)
Inventor
Andrew Neil Bowler
Bo Falck Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2455753A1 publication Critical patent/CA2455753A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

L'invention porte: sur de nouveaux dérivés de la 2,4-diaminothiazole de formule générale (I) inhibiteurs de la GSK-3 (glycogène synthase kinase-3), sur l'utilisation de ces composés comme médicaments; sur des préparations pharmaceutiques les contenant et sur des procédés de traitement utilisant lesdits composés et compositions. Lesdits composés peuvent servir à traiter des troubles, syndromes, maladies et états où l'inhibition de la GSK-3 (glycogène synthase kinase-3) est bénéfique, et spécialement: la diminution de la tolérance au glucose, le diabète de type 1, le diabète de type 2, l'obésité, la maladie d'Alzheimer et les troubles bipolaires.
CA002455753A 2001-08-03 2002-07-22 Nouveaux derives de la 2,4-diaminothiazole Abandoned CA2455753A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30995301P 2001-08-03 2001-08-03
US60/309,953 2001-08-03
DKPA200101175 2001-08-03
DKPA200101175 2001-08-03
PCT/DK2002/000508 WO2003011843A1 (fr) 2001-08-03 2002-07-22 Nouveaux derives de la 2,4-diaminothiazole

Publications (1)

Publication Number Publication Date
CA2455753A1 true CA2455753A1 (fr) 2003-02-13

Family

ID=26069057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002455753A Abandoned CA2455753A1 (fr) 2001-08-03 2002-07-22 Nouveaux derives de la 2,4-diaminothiazole

Country Status (6)

Country Link
EP (1) EP1417188A1 (fr)
JP (1) JP2004538315A (fr)
CA (1) CA2455753A1 (fr)
HU (1) HUP0401403A3 (fr)
MX (1) MXPA04000906A (fr)
WO (1) WO2003011843A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072577A1 (fr) * 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Derives thiazoles utilises comme antagonistes du recepteur npy
BR0313278A (pt) 2002-08-07 2005-07-05 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos
JP2007501824A (ja) * 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー Ｎｐｙアンタゴニストとしてのチアゾール誘導体
CA2562242A1 (fr) * 2004-04-13 2005-10-27 Icagen, Inc. Thiazoles polycyliques utilises en tant que modulateurs du canal des ions potassium
US7423053B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP2316458A1 (fr) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Derives de pyridazine destines a l'inhibition du desaturase-coa-stearoyl de l'humain
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
CA2587601C (fr) * 2004-12-03 2017-11-07 Rhode Island Hospital Diagnostic et traitement de la maladie d'alzheimer
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP1879591B8 (fr) * 2005-05-04 2012-04-04 DeveloGen Aktiengesellschaft Utilisation d'azapaullones pour la prevention et le traitement de troubles auto-immunes du pancreas
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
KR100670974B1 (ko) * 2006-09-18 2007-02-28 (주) 리드제넥스 티아졸 유도체의 조합화학적 방법에 의한 분자다양성구축기술
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU22400A (sh) * 1997-10-27 2003-08-29 Agouron Pharmaceuticals Inc. Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
EP1417188A1 (fr) 2004-05-12
HUP0401403A3 (en) 2005-11-28
JP2004538315A (ja) 2004-12-24
MXPA04000906A (es) 2004-11-22
WO2003011843A1 (fr) 2003-02-13
HUP0401403A2 (hu) 2004-10-28

Similar Documents

Publication Publication Date Title
CA2455753A1 (fr) Nouveaux derives de la 2,4-diaminothiazole
US6881746B2 (en) Glucagon antagonists/inverse agonists
WO2001056567A1 (fr) Derives de 2,4-diaminothiazole
ES2375872T3 (es) 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperacin-1-il)-piridacina, sus sales y solvatos, y su uso como antagonista del receptor h3 de la histamina.
US8362049B2 (en) Urea glucokinase activators
US11840527B2 (en) Non-fused thiophene derivatives and their uses
WO2004002480A1 (fr) Nouveaux antagonistes/agonistes inverses du glucagon
EP1463715A1 (fr) Nouveaux antagonistes de glucagon
US6762318B2 (en) Glucagon antagonists
DE60305037T2 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
WO2002032896A1 (fr) Derives de furazanyl-triazole destines au traitement de maladies
US20010039275A1 (en) Use of 2,4-diaminothiazole derivatives
US20070015757A1 (en) Novel Glucagon Antagonists/Inverse Agonists
RU2324685C2 (ru) Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
DE10252102A1 (de) Indolderivate
US20040210063A1 (en) Novel 2,4-diaminothiazole derivatives
AU2002355623A1 (en) Novel 2,4-diaminothiazole derivatives
MXPA02005092A (es) Nuevas sulfoniloxazolaminas.
US20050059611A1 (en) Glucagon antagonists/inverse agonists
MX2008000973A (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060724